East West Eye Institute

Premiere Practice Management

Glaucoma

Ocular Hypertension

Open-Angle Glaucoma

Hypertension

Dry Eye Syndromes

Keratoconjunctivitis Sicca

Capsule Opacification

Refractive Errors

Cataract

Eye Diseases

Timolol Maleate

DE-126

APP13007

K-161

Dupilumab

Netarsudil

DE-117

Santen

Aerie Pharmaceuticals

Alcon

Andover Eye Associates

Formosa Pharmaceuticals

Icare

Kowa

condition

Keratoconjunctivitis

allSponsorName

Regeneron Pharmaceuticals

Statistics & Data Corporation

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

Premiere Practice Management | East West Eye Institute

Site insights

Work at this site?

Active trials

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

Trial sponsors